AI Article Synopsis
- * NBC is characterized by a complex interplay of factors affecting bladder control and urinary urges, which is essential to understand for proper diagnosis and treatment.
- * Given the rise in cases of interstitial cystitis, it's important for healthcare providers to consider NBC if initial treatments like anticholinergics or antidepressants are ineffective.
Article Abstract
The concept of non-bacterial cystitis (NBC) combines sterile urine and cystitic symptoms as well as inflammatory changes, in particular in the mucosa and submucosa of the bladder. It includes a multiplicity of vicious circles along the entire continence reflex. An understanding of NBC presupposes knowledge of the origin of the normal urinary urge and its successful control. Against the background of the steadily increasing incidence of interstitial cystitis (often irreversible end-stage NBC), it is suggested here that in the face of a failure of first-line therapeutics (anticholinergics, cyclic antidepressants or oestrogens), one must consider without delay the possible presence of NBC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00042307-200009000-00003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report.
Front Immunol
July 2024
Department of Pulmonary and Critical Care Medicine, Shanghai Key Discipline for Respiratory Diseases, Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Immune checkpoint inhibitors (ICIs) including anti-programmed death cell protein 1 (anti-PD1) and anti-programmed cell death-ligand 1 (PD-L1), by disinhibiting the antitumor responses of lymphocytes, have extended survival benefits for patients in lung cancer. ICIs can also lead to a wide spectrum of immune-related adverse events (irAEs), due to dysregulation of immune reactions. Here, we report a 27-year-old female patient with adenocarcinoma of the lung treated with pembrolizumab-combined chemotherapy treatment, who complained of urinary irritation symptoms.
View Article and Find Full Text PDFAcute Non-infectious Cystitis Secondary to Immune-Related Adverse Events in a Patient Receiving Pembrolizumab for Treatment of Non-small Cell Lung Cancer: A Case Report.
Cureus
March 2024
Hematology and Medical Oncology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Article Synopsis
- * A rare case is reported of a 71-year-old man with lung adenocarcinoma who developed hemorrhagic cystitis likely due to pembrolizumab while having a chronic Foley catheter and experiencing ongoing hematuria.
- * After normal cystoscopy and unsuccessful antibiotic treatment for a urinary infection, the suspicion of drug-induced cystitis led to treatment with prednisone and temporary cessation of pembrolizumab, resulting in symptom improvement.
Introduction: Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune-related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms.
Case Presentation: The patient was a 60-year-old man with primary lung cancer who was receiving long-term nivolumab therapy.
Non-bacterial Cystitis With Increased Expression of Programmed Cell Death Ligand 1 in the Urothelium: An Unusual Immune-Related Adverse Event After Atezolizumab Administration for Metastatic Breast Cancer.
Cureus
May 2022
Department of Breast Surgery, Breast Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, JPN.
We report a case of non-bacterial cystitis that occurred after administration of atezolizumab, an antibody against programmed cell death ligand 1 (PD-L1). This cystitis was considered an immune-related adverse event (irAE). A 67-year-old woman with advanced breast cancer (cT4bN1M1, cStage IV) was treated with atezolizumab and nanoparticle albumin-bound (nab) paclitaxel.
View Article and Find Full Text PDFNon-bacterial cystitis secondary to pembrolizumab: A case report and review of the literature.
Curr Probl Cancer
August 2022
Department of Pathology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
In recent years, immune checkpoint inhibitors were successfully introduced to various of cancer therapy. Pembrolizumab, an antibody to programmed cell death-1 (PD-1), which is was approved for treatment of any adult or pediatric, unresectable or metastatic solid tumor. However, just as chemotherapeutics, immune checkpoint inhibitors have many side effects, which are named as immune-related adverse events.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!